



**Covid-19 Evidence Accelerator
Virtual Public Meeting**

October 20, 2022

1-4 PM ET

AGENDA

1 p.m. Welcome and Introduction

Speaker: Susan C. Winckler, RPh, Esq., CEO, Reagan-Udall Foundation for the FDA

1:03 p.m. Opening Remarks

Speaker: Namandjé N. Bumpus, PhD, Chief Scientist, FDA

1:08 p.m. Remarks

Speaker: Robert M. Califf, MD, MACC, Commissioner of Food and Drugs

1:10 p.m. Keynote Speech

Speaker: Amy Abernethy, MD, PhD, President of Clinical Studies Platforms, Verily

1:25 p.m. Session One: FDA Perspectives on the COVID-19 Evidence Accelerator

Moderator: Jeff Allen, PhD, President and CEO, Friends of Cancer Research

Panel:

- Jacqueline A. O'Shaughnessy, PhD, Office of the Chief Scientist, FDA
- Peter Marks, MD, PhD, Center for Biologics Evaluation and Research, FDA
- Patrizia Cavazzoni, MD, Center for Drug Evaluation and Research, FDA
- Sara Brenner, MD, MPH, Center for Devices and Radiological Health, FDA

2:10 p.m. Session Two: Research Findings and Methodologies

Moderator: Carla Rodriguez-Watson, PhD, MPH, Director of Research, Reagan-Udall Foundation for the FDA

Panel:

- Nicolle Gatto, PhD, MPH, Aetion, Inc
- Sandy Leonard, MPH, HealthVerity
- Vince Lo Re III, MD, MSCE, University of Pennsylvania
- Anand Chokkalingham, PhD, Gilead Sciences
- Nancy Lin, ScD, IQVIA
- Aloka Chakravarty, PhD, Office of the Commissioner, FDA

3:10 p.m. Session Three: How COVID-19 and the Evidence Accelerator Have Shaped the Use of Real-World Data

Moderator: Susan C. Winckler, RPh, Esq, CEO, Reagan-Udall Foundation for the FDA

Panel:

- Nancy Dreyer, PhD, MPH, IQVIA
- Adrian Hernandez, MD, MHS, Duke University of School of Medicine
- Nilay Shah, PhD, Delta Airlines

3:50 p.m. Closing Fireside Chat

Speakers:

- Susan C. Winckler, RPh, Esq., CEO, Reagan-Udall Foundation for the FDA
- Ellen V. Sigal, PhD, Chairperson and Founder, Friends of Cancer Research, and Chair of Board of Directors, Reagan-Udall Foundation for the FDA
- Andrew C. von Eschenbach, MD, 20th Commissioner of Food and Drugs, and Board member, Reagan-Udall Foundation for the FDA

4 p.m. Adjourn Meeting